Drug-gene interactions between genetic polymorphisms and antihypertensive therapy

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Genetics

Background:

• Genetic factors can significantly impact individual responses to antihypertensive medications.
• Previous candidate gene studies have yielded inconclusive results regarding drug-gene interactions in hypertension treatment.
• Observational data suggests potential benefits of diuretics in hypertensive patients with specific alpha-adducin gene variants.

Purpose of the Study:

• To review and synthesize evidence on drug-gene interactions in antihypertensive therapy.
• To identify specific genetic polymorphisms associated with cardiovascular and blood pressure responses to different drug classes.
• To assess the current state of research and highlight areas for future investigation.

Main Methods:

• Review of candidate gene studies investigating genetic polymorphisms and their influence on antihypertensive drug response.
• Analysis of reported interactions between specific genes (e.g., alpha-adducin, endothelial nitric oxide synthase, G protein subunit, ACE) and drug classes (e.g., diuretics, beta-blockers, AT(1) receptor antagonists, ACE inhibitors, calcium channel blockers).
• Evaluation of observational evidence linking genetic variants to clinical outcomes like myocardial infarction and stroke.

Main Results:

• Limited evidence for drug-gene interactions in most candidate gene studies.
• Observational data suggests the 460 W allele of the alpha-adducin gene may reduce myocardial infarction and stroke risk with diuretics.
• Identified interactions include polymorphisms in endothelial nitric oxide synthase and alpha-adducin with diuretics, G protein subunit and beta-adrenoceptor antagonists, and ACE gene with AT(1) receptor antagonists.
• ACE inhibitors showed interaction with the ACE insertion/deletion (I/D) polymorphism, affecting AT(1) receptor mRNA, left ventricular hypertrophy, and arterial stiffness.
• Drug-gene interactions between calcium channel antagonists and ACE I/D polymorphism regarding arterial stiffness were also reported.

Conclusions:

• Current evidence from candidate gene studies on drug-gene interactions in hypertension is inconclusive due to variable study quality and methodological issues.
• Further high-quality research is necessary to validate observed drug-gene interactions and their clinical significance.
• Pharmacogenomic approaches hold promise for personalized antihypertensive therapy, but require robust validation.